A European Medicines Agency panel said on Friday it recommended granting marketing approval to Sanofi and Regeneron’s experimental drug to treat rheumatoid arthritis.
The Committee for Medicinal Products for Human Use gave a positive opinion on the drug, Kevzara, citing its ability to reduce the signs and symptoms of rheumatoid arthritis.
Sarilumab, the active substance of Kevzara, a treatment for adult patients with moderate to severe rheumatoid arthritis, works by blocking a protein called IL-6, which is associated with inflammation.
The panel’s opinion will now be reviewed by the EMA.
In October, U.S. regulators declined to approve sarilumab because of manufacturing deficiencies at a Sanofi plant in France.
Regeneron said in February that it was planning to resubmit a marketing application to the U.S. Food and Drug Administration for sarilumab.
The drug has already been approved by Canadian health regulators to treat rheumatoid arthritis.
More than 23 million people worldwide suffer from rheumatoid arthritis. Current treatments include the widely used methotrexate as well as non-steroidal anti-inflammatory drugs.
Other IL-6 inhibitors for rheumatoid arthritis include Roche Holding AG’s approved Actemra and Johnson & Johnson’s experimental sirukumab.
Last Friday, the FDA declined to approve a new rheumatoid arthritis drug, Olumiant, made by Eli Lilly and Co and partner Incyte Corp.
The information herein on "Experimental Arthritis Drug Kevzara Approved" is not intended to replace a one-on-one relationship with a qualified health care professional, licensed physician, and is not medical advice. We encourage you to make your own health care decisions based on your research and partnership with a qualified health care professional.
Our information scope is limited to chiropractic, musculoskeletal, physical medicines, wellness, sensitive health issues, functional medicine articles, topics, and discussions. We provide and present clinical collaboration with specialists from a wide array of disciplines. Each specialist is governed by their professional scope of practice and their jurisdiction of licensure. We use functional health & wellness protocols to treat and support care for the injuries or disorders of the musculoskeletal system.
Our videos, posts, topics, subjects, and insights cover clinical matters, issues, and topics that relate to and support, directly or indirectly, our clinical scope of practice.*
Our office has made a reasonable attempt to provide supportive citations and has identified the relevant research study or studies supporting our posts. We provide copies of supporting research studies available to regulatory boards and the public upon request.
We understand that we cover matters that require an additional explanation of how it may assist in a particular care plan or treatment protocol; therefore, to further discuss the subject matter above, please feel free to ask Dr. Alex Jimenez or contact us at 915-850-0900.
We are here to help you and your family.